Vincenzo Favilla
Papers
1
Total Citations
50
H-Index
1
About
Vincenzo Favilla is a prominent urological researcher whose work focuses on improving the early detection and risk stratification of prostate cancer, particularly in the context of active surveillance. His major contributions center on integrating novel biomarkers—such as the Prostate Health Index (PHI) and PCA3—with established clinical criteria to more accurately predict insignificant prostate cancer. In his highly cited 2015 study (50 citations), Favilla demonstrated that combining PHI and PCA3 significantly enhances the prognostic performance of the PRIAS and Epstein criteria, helping to identify men who can safely avoid unnecessary treatment. This work has direct implications for reducing overtreatment and improving patient quality of life. Favilla’s research is widely recognized for bridging the gap between molecular diagnostics and clinical decision-making, offering a more personalized approach to prostate cancer management. His findings have been instrumental in refining active surveillance protocols, making him a key figure in the ongoing effort to balance cancer control with the preservation of urinary and sexual function.
Research Focus
Key Achievements
Top Papers
- 1